Investor Presentaiton

Reported revenue grew 4% in Q3, reflecting solid organic growth of 8% and significant headwind from exchange rates development Q3 2022/23 Revenue development (DKKm) 450 5,849 +259m DKK -191 6,108 Reported revenue Q3 2021/22 Organic growth (constant currencies) Acquired growth Currency effect Reported revenue Q3 2022/23 Growth 7.7% 0.0% -3.3% 4.4% Q3 2022/23 highlights Organic growth was 8% or DKK 450 million, driven by: • • Continued solid momentum in Chronic Care across regions China Ostomy Care grew double-digit, due to a lower baseline and normalized hospital activity and new patients' inflow Strong quarter in Continence Care with solid contribution across product groups, incl. Collecting Devices, following backorder resolution Continued solid momentum in Voice and Respiratory Care, driven by both Laryngectomy and Tracheostomy Wound Care growth driven by double-digit growth in China, while growth in Europe was held back by backorders Continued solid momentum in Interventional Urology with broad-based growth across geographies and businesses Foreign exchange rates had a negative impact of DKK 191 million or -3.3%-points on reported growth, mainly related to the depreciation of the USD, GBP, and several emerging markets currencies against DKK 11 Coloplast

View entire presentation